SUMMARY OF BASIC LEASE INFORMATIONExtension Option Rider • March 21st, 2019 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations
This Lease, which includes the preceding Summary and the exhibits attached hereto and incorporated herein by this reference (the Lease, the Summary and the exhibits to be known sometimes collectively hereafter as the “Lease”), dated as of the date set forth in Section 1 of the Summary, is made by and between WALTON TORREY OWNER A, L.L.C., a Delaware limited liability company (“Landlord”), and TP THERAPEUTICS, INC., a Delaware corporation “Tenant”).
TP THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for YISHAN (PETER) LI, PH.D., M.B.A.Employment Agreement • March 21st, 2019 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (this “Agreement”), is made and entered into effective as of September 29, 2018 (the “Effective Date”), by and between Yishan (Peter) Li (“Executive”) and TP Therapeutics, Inc. (the “Company”).
TP THERAPEUTICS, INC. CONSULTING AGREEMENT EFFECTIVE DATE: November 14, 2017Consulting Agreement • March 21st, 2019 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • California
TURNING POINT THERAPEUTICS, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for JINGRONG JEAN CUI, PH.D.Executive Employment Agreement • March 21st, 2019 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • California
This Amended and Restated Executive Employment Agreement (this “Agreement”), is made and entered into effective as of January 17, 2019 (the “Effective Date”), by and between Jingrong Jean Cui (“Executive”) and Turning Point Therapeutics, Inc. (the “Company”).
TP THERAPEUTICS, INC. FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • March 21st, 2019 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • California
THIS FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of October 18, 2018, by and among TP THERAPEUTICS, INC., a Delaware corporation (the “Company”) and certain investors of the Company (referred to hereinafter as the “Investors” and each individually as an “Investor”), including the purchasers of Series D Preferred Stock listed on EXHIBIT A hereto.
